Procept BioRobotics’ $118 Million Round Funding


Cooley advised Procept BioRobotics on its $118 million equity financing round led by Viking Global Investors. Partner Mark Weeks led the Cooley team advising Procept.

PROCEPT BioRobotics has raised $118 million in an equity financing led by new investor Viking Global Investors LP, with participation from new investor Perceptive Advisors and existing investors, including CPMG, Inc.

The financing will support the worldwide commercialization of the company’s Aquablation therapy for the minimally invasive treatment of benign prostatic hyperplasia (BPH).

In addition to Viking Global, the round included participation from new investor Perceptive Advisors and existing investor CPMG. The new funds will support the worldwide commercialization of Procept’s Aquablation therapy for the minimally invasive treatment of benign prostatic hyperplasia (BPH).

Procept’s Aquabeam System is the first FDA-granted surgical robot providing autonomous tissue removal for the treatment of BPH. It is commercially available in the US, Canada, Australia, New Zealand and select European markets.

Based in Silicon Valley, Procept is a privately held surgical robotics company enabling better patient care by developing transformative solutions in urology.

Cooley advised Procept BioRobotics with a team including Mark Weeks (Picture), Anita Vasudevan, Daniel Elefant and Cameron Hajialiakbar.

Involved fees earner: Mark Weeks – Cooley LLP; Anita Vasudevan – Cooley LLP; Daniel Elefant – Cooley LLP; Cameron Hajialiakbar – Cooley LLP;

Law Firms: Cooley LLP;

Clients: Procept Biorobotics Corp.;

Avatar

Author: Ambrogio Visconti